Loading...
Back to narrative

WRBY: Renewed Partnerships Will Support Improved Engagement And 2025 Outlook

Update shared on 22 Nov 2025

Fair value Decreased 12%
n/a
n/a
AnalystConsensusTarget's Fair Value
n/a
Loading
1Y
27.0%
7D
64.1%

Analysts have reduced their average price target for Warby Parker from approximately $25.08 to $22.17. They cite slower revenue growth trends and ongoing concerns about near-term topline outlook and retail risks.

Analyst Commentary

Street research following the recent results at Warby Parker reveals a mix of cautious and optimistic perspectives. Analysts have weighed in on the company's current valuation, revenue trends, and growth execution, resulting in both supportive and skeptical viewpoints.

Bullish Takeaways

  • Some analysts continue to see long-term growth potential for Warby Parker, highlighting the company's ability to deliver solid adjusted EBITDA even in the face of revenue setbacks.
  • The reaffirmation of the full-year EBITDA outlook has been noted as a positive sign for operational execution and cost management.
  • Supporters point to sustained buy recommendations, with some optimism that the company can recover its growth trajectory over time.

Bearish Takeaways

  • Cautious analysts emphasize the continued slowdown in revenue trends, particularly highlighting recent declines in younger consumer engagement and the impact on topline growth.
  • There are growing concerns around the persistence of these weak sales trends into upcoming quarters, raising doubts about a near-term recovery in topline performance.
  • Current premium valuations are being questioned by several research notes, with skepticism that investors are adequately compensated given potential risks to retail economics and the pace of multiple improvement.
  • Overall, uncertainty has increased regarding Warby Parker's ability to deliver consistent mid-teens or higher revenue growth, which is seen as necessary to justify current share prices.

What's in the News

  • The company issued updated earnings guidance for full year 2025, projecting net revenue of $871 million to $874 million. This would represent growth of approximately 13% (Key Developments)
  • The company announced a three-year partnership with Texas Longhorns quarterback Arch Manning. The partnership includes new eyewear collections, a commercial debut, and local Austin community initiatives through the Pupils Project vision program (Key Developments)

Valuation Changes

  • Consensus Analyst Price Target: Lowered from $25.08 to $22.17, reflecting a more cautious outlook on shares.
  • Discount Rate: Increased slightly from 8.41% to 8.44%, suggesting modestly higher perceived risk.
  • Revenue Growth: Reduced from 14.6% to 12.9%, indicating tempered expectations for top-line expansion.
  • Net Profit Margin: Improved from 6.35% to 8.36%, pointing to expectations of better bottom-line profitability.
  • Future P/E: Dropped significantly from 51.4x to 34.8x, implying a less optimistic view of forward earnings valuation.

Have other thoughts on Warby Parker?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.